18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Heading to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
New and different therapies emerging through uveitis pipeline
June 12th 2017Local therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
NICE recommends dexamethasone adalimumab for uveitis
June 8th 2017The UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Data clearly demonstrates bevacizumab’s inferiority for DME
June 7th 2017All three anti-vascular endothelial growth factor (anti-VEGF) agents that are commercially available have demonstrated efficacy for the treatment of diabetic macular edema (DME). However, it is clear from the results of clinical trials that outcomes with bevacizumab are not as good as those obtained using ranibizumab or aflibercept, according to Jean-François Korobelnik, MD.
Vitrectomy beats scleral buckling in rhegmatogenous retinal detachment study
June 7th 2017Eyes operated on with pars plana vitrectomy needed fewer reoperations over 180 days than eyes subjected to scleral buckling (SB) in a retrospective comparison of patients with rhegmatogenous retinal detachment (RRD).
Retina surgeon’s AMD regimen at center of Medicare fraud case
May 25th 2017Earlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.
Treating ROP: Laser associated with high success rate for retinopathy of prematurity
May 23rd 2017Laser photocoagulation is a time-tested, well-defined, and effective treatment for retinopathy of prematurity (ROP) with requirements for follow-up that are much more manageable compared with anti-vascular endothelial growth factor (anti-VEGF) therapy, argued David K. Wallace, MD, MPH.
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I disease
May 23rd 2017Anti-VEGF therapy for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD.
Genetic testing initiative for inherited retinal diseases shows great promise
May 20th 2017I have been encouraged as a retinal specialist with all the excitement and promising new treatments in gene therapy. Given that there are several retinal diseases with known inherited patterns and confirmed genetic loci responsible for the clinical manifestations, our field is primed to benefit from the expansion of knowledge in this arena.
New molecule enhances effect of anti-VEGF therapy for DME
May 10th 2017Activation of Tie2–as a result of subcutaneous administration of AKB-9778 (Aerpio Therapeutics) in combination with an anti-vascular endothelial growth factor (anti-VEGF) therapy–enhances the effect of an anti-VEGF drug on diabetic macular edema (DME).
Insights from anti-VEGF pivotal DME trials
May 10th 2017Analyses of data collected in the RISE/RIDE and VIVID/VISTA clinical trials provide important messages about the efficacy and safety of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) for treatment of diabetic macular edema (DME).
Year-2 Protocol T data paints different scenario from year-1
April 12th 2017The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol T-the first head-to-head-to-head comparison among aflibercept (Eylea, Renegeron Pharmaceuticals), ranibizumab (Lucentis, Genentech), and bevacizumab (Avastin, Genentech)-found in its first-year results that all three agents improved vision and reduced edema effectively.
DAVE study found little benefit of anti-VEGF/PRP for DME
April 12th 2017The scientific community knows that vascular endothelial growth factor (VEGF) causes increased, vascular permeability, resulting in diabetic macular edema (DME) in the ischemic retina, but how to stop the VEGF drive remains the challenge.
New technology takes invisibility cloak off in retinal imaging
April 10th 2017New imaging technologies, such as ultra-wide-field fluorescein angiography and optical coherence tomography angiography, are providing more details about retinal diseases than previous imaging technologies, leading to better understanding of disease processes.
4 pattern recognition skills that are relevant in clinic
April 10th 2017Knowledge of pathologic patterns is necessary in medical retina, especially patterns that are unusual or rare. Pattern recognition skills are essential in medical retina. Lawrence Yannuzzi, MD, highlights four patterns that he believes are relevant in clinical practice and should be recognized–and not missed–by retinal specialists.
Investigational wet AMD therapies aim for innovative targets
March 24th 2017Many investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Failed cell therapy study offers positives, raises new questions
March 24th 2017Patients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Novel anti-VEGF-A agent shows promise for prolonged DME activity
March 8th 2017Abicipar pegol (Allergan/Molecular Partners) met its primary and key secondary endpoints and demonstrated an acceptable overall safety profile in a phase II trial investigating use of the novel anti-VEGF-A agent for treatment of diabetic macular edema (DME).
Sustained-release corticosteroid implant improves, slows progression of diabetic retinopathy
March 8th 2017Sustained intraocular delivery of fluocinolone acetonide (FAc) using the FAc 0.19 mg intravitreal implant (Iluvien, Alimera Sciences) improves and slows progression of diabetic retinopathy (DR), according to findings of post-hoc analyses of data from the pivotal Fluocinolone Acetonide for Diabetic Macular Edema (FAME) trials.
Laser still useful diabetic eye disease tool in anti-VEGF era
February 25th 2017Although clinical trial results have advanced anti-VEGF injections to the forefront of treatment for diabetic eye disease, laser photocoagulation continues to be an important modality for the management of diabetic macular edema (DME) and diabetic retinopathy (DR), said Elias Reichel, MD, at the inaugural Retina World Congress.